Source comparison
CJC-1295 No DAC & Ipamorelin Legal to Purchase: Research vs Personal Use Comparison
Institutional research laboratory with IRB oversight Fully legal under research chemical exemption Institutional affiliation proof, research protocol summary, authorized purchase order FDA registration, batch-specific CoA, purchaser verification Minimal—compli
This comparison does not assign a generated winner or score.
- Institutional research laboratory with IRB oversight
- Fully legal under research chemical exemption
- Institutional affiliation proof, research protocol summary, authorized purchase order
- FDA registration, batch-specific CoA, purchaser verification
- Minimal—compliant transaction protected by FFDCA research exemption
- This is the only acquisition pathway with established legal protection under current FDA interpretation
- Individual consumer claiming 'personal research'
- Illegal—FFDCA Section 505(a) violation
- None accepted by compliant suppliers
- Compliant suppliers will not fulfill order
- High—both buyer and seller exposed to enforcement action
- The research disclaimer provides zero legal protection when institutional affiliation cannot be demonstrated
- Compounding pharmacy prescription for off-label use
- Legal grey area—FDA enforcement discretion
- Valid prescription from licensed provider
- 503A or 503B registration (currently contested for growth hormone peptides)
- Moderate—FDA issued guidance discouraging GH secretagogue compounding in 2023
- Regulatory landscape remains uncertain; some pharmacies continue fulfilling prescriptions, others have ceased
- Import from international supplier without prescription
- Illegal—FFDCA import restrictions + potential Controlled Substances Act violation
- None—importation itself violates law
- International vendors not subject to U.S. regulation
- Very high—CBP confiscation + potential criminal referral
- Peptide imports are subject to FDA detention and seizure even when the compound itself is not scheduled